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OBJECTIVES: FIBROSCAN® is an ultrasound elastography
based non-invasive liver ﬁbrosis assessment device. This new
technology is aimed to replace or diminish the number of inva-
sive liver biopsy performed. The purpose of this study was to
compare, in terms of life expectancy and lifetime costs, a 5-year
periodic liver biopsy follow-up of HCV infected patients to an
annual liver ﬁbrosis assessment using FIBROSCAN® which
is assumed to allow an earlier antiviral treatment initiation.
METHODS: A discrete event simulation was developed. The
model simulates the lifetime follow-up of a cohort of 10,000
HCV newly infected individuals. The Health Insurance perspec-
tive was used and costs were discounted using a 3% rate. Direct
medical costs were derived from French ofﬁcial sources. The
model was populated with published clinical trial data and other
published studies. RESULTS: Death rate from hepatic mortality
was reduced by 0.68% (68 deaths prevented over the whole
cohort) with FIBROSCAN®. The survival gain was 0.07 year/
patient that is 10.3 years for the 68 avoided deaths. The average
cost of the disease was of €11,545/patient with FIBROSCAN®
compared with €12,510/patient in the case of biopsy. When
biopsy was performed every 3 years, there were no survival gain
but savings of 3, 722€/patient. At every 10 years, FIBROSCAN®
follow-up remained a cost-effective strategy allowing a 3.53%
reduction of hepatic death (353 deaths prevented over the whole
cohort) and a survival gain of 0.39 year/patient (p < 0,001). In
this latter case, the cost per life year gained was 810€ which is
largely below the ratios commonly cited in such analysis. CON-
CLUSION: FIBROSCAN® is a dominant strategy. Compared to
a periodic hepatic ﬁbrosis follow-up with liver biopsy, FIBROS-
CAN® helps reducing hepatic mortality, increasing patients’ life
expectancy and diminishing the costs associated with managing
patients chronically infected with HCV.
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OBJECTIVES: Despite good vaccination coverage rates and
good a-cellular pertussis vaccine efﬁcacy the incidence is still
relatively high in The Netherlands. Pertussis is most severe in
infants too young for already having completed the primary
immunization schedule. For protection of young infants (below
one year of age) further strategies should be considered. It is
known that household members are an important source of
transmission for these infants. The objective of this study was to
analyze cost-effectiveness of speciﬁc vaccination strategies in The
Netherlands explicitly targeting pertussis in these young infants.
METHODS: Data were extracted from national registries on
incidence, hospitalizations and neonatal intensive care. Addition-
ally, literature and expert consultations were used to complete
information on morbidity and accompanying direct costs for
pertussis in infants. A static decision analysic model was
constructed for estimating health outcomes and costs potentially
associated with different vaccination strategies. The strategies
investigated were cocooning (father and mother), pre- and post-
pregnancy maternal immunization, all to protect the infant for
transmission of pertussis in the household setting. RESULTS:
Relatively, the potential most effective strategy would to be
cocooning. However this would also be the most expensive.
Compared to do-nothing, incremental cost-effectiveness of the
three strategies varied from €15,000 to just over €100,000 per
hospitalization averted in the base case. Results appeared to be
robust in sensitivity analysis. Under plausible assumptions,
pre-pregnancy maternal immunization could well be the most
cost-effective strategy. We note that the overall impact on total
numbers of infections among young infants obviously crucially
depends on the vaccination coverage achieved. CONCLUSION:
Cost-effectiveness analysis as presented here is crucial in the
Dutch decision making concerning additional pertussis vaccina-
tion strategies to protect young infants against severe disease.
Further research is needed to fully assess the effectiveness of these
strategies, inclusive the application of dynamical models for the
spread of pertussis.
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OBJECTIVES: Hepatitis C is a disease affecting approximately
180 million people worldwide (WHO 2006) and is one of the
main causes of chronic hepatic disease. HCV infection progresses
to chronic form in 80% of infected individuals. Approximately
20% progress to cirrhosis over 20 years and, consequently, a
high risk of developing hepatocellular carcinoma population.
Our objective is to assess the incremental cost-effectiveness
ratio (ICER) of peginterferon-alfa-2a (40 KD) plus ribavirin
(PEG + RBV) versus interferon-alfa-2b plus ribavirin (IFN +
RBV) in the treatment of patients with chronic hepatitis
C, genotypes 2 and 3 in the Brazilian payer perspective.
METHODS: A Markov model was built to estimate the clinical
and economic impact related to the incorporation of
peginterferon-alfa-2a (40 KD). Clinical stages were based on
liver histology, forms of cirrhotic decompensation, liver cancer
and liver transplantation. A Delphi panel was performed for
evaluating the direct medical resources related to each clinical
stage in chronic hepatitis C, as well as costs from treatment with
peginterferon-alfa-2a (40 KD), interferon alfa-2b and ribavirin.
Effectiveness of treatment with peginterferon-alfa-2a (40 KD)
was obtained from a multicenter, controlled, randomized trial
involving 1,121 naive patients with chronic hepatitis C (Fried,
M. W. et al, 2002). We have assumed a discount rate of 3.5% for
costs and outcomes according to NICE and a lifetime horizon. A
sensitivity analysis was conducted using second-order Monte
Carlo simulation. Tested parameters were costs per stage, treat-
ment costs, discount rate, response rate to treatment and early
patient distribution. RESULTS: The ICER of PEG + RBV versus
IFN + RBV was approximately R$18,627 per life year gained
(LYG). The 95% conﬁdence interval for the ICER ranged from
R$9,571 to R$29,090. CONCLUSION: The study suggests
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peginterferon-alfa-2a (40 KD) to be a cost-effective therapy for
the private health care system in Brazil.
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OBJECTIVES: Studies have shown similar clinical cure rates and
shorter length of stay (LOS) for linezolid compared to vancomy-
cin in patients with complicated skin and soft tissue infections
(cSSTI) due to suspected or proven methicillin-resistant Staphy-
lococcus aureus (MRSA). This study examined the clinical and
economic consequences of using linezolid vs. vancomycin from
the French health system perspective. METHODS: A decision-
analytic model followed an average patient from initiation of
empiric treatment until successful 1st-line treatment, death, or
2nd-line treatment failure. Efﬁcacy data were derived from pub-
lished clinical trials. Resource utilization patterns were collected
through structured interviews with 4 French physicians experi-
enced in treating cSSTI. Costs from ofﬁcial price and tariff lists
were applied to antibiotics therapy, hospitalisation (by ward
type), isolation, tests, adverse events, and post-discharge.
Patients could be discharged to oral linezolid. The base case used
therapy duration and LOS from the expert panel. Outcomes
included total cost per patient, and cost per cure. RESULTS:
Average total cost per episode was €7784 for linezolid vs. €8514
for vancomycin (cost savings of €730 mostly due to reduction in
hospitalization costs from earlier discharge). Mean LOS after
two lines of treatment was 10.7 days for linezolid vs. 13.3 days
for vancomycin. An additional 0.5% of patients treated with
linezolid (98.5%) vs. vancomycin (98.0%) were cured. Slight
increase in effectiveness and reduced cost made linezolid the
dominant treatment strategy. One-way sensitivity analysis on
selected parameters (50% variation above or below baseline),
and a conservative scenario with simultaneous changes in key
parameters, did not change the overall conclusions (linezolid
remained cost-saving). CONCLUSION: This model showed that
linezolid could be cost saving when treating patients with cSSTI
due to suspected MRSA, while overall clinical cure was similar.
Linezolid could therefore be considered an efﬁcient strategy for
treating cSSTI in France.
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OBJECTIVES: Linezolid has demonstrated improved survival
and clinical cure rates in hospitalised patients with nosocomial
pneumonia (NP) caused by known or suspected methicillin-
resistant Staphylococcus aureus (MRSA). This study assessed the
cost-effectiveness of linezolid vs. vancomycin from the perspec-
tive of the French health system. METHODS: A decision-
analytic model followed an average patient from initiation of
empiric treatment until successful 1st-line treatment, death, or
2nd-line treatment failure. Efﬁcacy data were derived from pub-
lished clinical trials. Five French physicians experienced in treat-
ing NP provided resource utilization data through structured
interviews. Costs from ofﬁcial price and tariff lists were applied
to antibiotic therapy, hospitalisation (by ward type), isolation,
tests, and adverse events. The model applied similar length of
successful 1st-line treatment for linezolid and vancomycin. The
model base case conservatively assumed that length of stay was
equal to therapy duration. Outcomes included total cost per
patient, cost per cure, cost per death avoided, and cost per life
year gained. RESULTS: An additional 7.6% of patients treated
with linezolid (70.9%) vs. vancomycin (63.2%) were cured.
Average total cost per episode was €16,732 for linezolid vs.
€15,375 for vancomycin, Modelled survival was 80.4% (lin-
ezolid) vs. 69.7% (vancomycin), resulting in an average 2.0
life-years gained per linezolid patient in a 65-year-old cohort
(14.9 vs. 13.0 years). Costs per life-year gained (excluding future
costs) and death avoided were €685 and €12,727, respectively.
One-way sensitivity analysis on selected parameters (50%
variation above or below baseline) did not change the overall
conclusions. CONCLUSION: Improved clinical outcomes, but
increased cost per episode were calculated for linezolid-treated
patients. The results suggest that linezolid can be considered a
cost-effective alternative for treating patients with NP due to
suspected MRSA in France.
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OBJECTIVES: Linezolid has shown efﬁcacy in the treatment of
methicillin-resistant Staphylococcus aureus (MRSA) infections,
including nosocomial pneumonia (NP). In patients with MRSA-
NP, survival and clinical cure rate was higher for patients treated
with linezolid (80% and 59%, respectively) than those treated
with vancomycin (63.5% and 35.5%, respectively). The objec-
tive of this study is to asses the economic impact of these clinical
outcomes in the Spanish setting. METHODS: A retrospective
decision-analytical model from the hospital perspective was
applied to pooled data from 2 prospective, randomized,
controlled-double-blind studies. The model described possible
treatment outcomes for patients beginning empiric MRSA-NP
treatment. Clinical and other parameters were obtained from
published trials and from an expert panel, comprised of 5
Spanish experts experienced in treating NP. Resource use was
estimated by the expert panel. Only direct costs (€2007) were
considered. The model assumed 50% of suspected MRSA
patients had proven MRSA. Model outputs included costs/
patient, cost/death avoided, cost/life-year gained (LYG), and cost/
cure. Sensitivity analyses were carried out to test the robustness
of the model. RESULTS: The overall clinical cure rate was 11%
greater for linezolid than for vancomycin (71% versus 60%).
Average total treatment cost was €16,602 for linezolid versus
€15,823 for vancomycin-treated patients; incremental cost
€6829. Death rates were 21% (linezolid) versus 34% (vancomy-
cin), with an average 1.9 LYG per linezolid patient in a 65-year-
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